Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
(Stage 2: Consensus Profiles)
(Stage 2: Consensus Profiles)
Line 8: Line 8:
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | Magnetic Resonance Elastography of the Liver 2018-05-02]]  
+
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]
 +
 
 +
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.02.11.docx|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-02-11]]
 +
 
 +
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
  
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
 
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
 
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
 
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
 
  
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.02.11.docx|QIBA Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2018.02.11]]
+
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
 
   
 
   
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|QIBA DCE-MRI Quantification Profile, v 1.0 2012-08-08]]
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===

Revision as of 19:57, 18 May 2018

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Stage 3: Technically Confirmed Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Submit comments using the online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; submit additional forms as necessary)

  • There are currently no Profiles open for Public Comment

Public Comment closed for the following Profiles (comment resolution is currently underway):

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. * Specific Profile Title, * Quantitative Imaging Biomarkers Alliance. * Version. * Profile Stage. * QIBA, * Date. * Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement


See Also